Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa.
<h4>Background</h4>Antivenom is the treatment of choice for snakebite, which annually kills an estimated 32,000 people in sub-Saharan Africa and leaves approximately 100,000 survivors with permanent physical disabilities that exert a considerable socioeconomic burden. Over the past two d...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-10-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://doi.org/10.1371/journal.pntd.0005969 |
| _version_ | 1819281592490655744 |
|---|---|
| author | Robert A Harrison George O Oluoch Stuart Ainsworth Jaffer Alsolaiss Fiona Bolton Ana-Silvia Arias José-María Gutiérrez Paul Rowley Stephen Kalya Hastings Ozwara Nicholas R Casewell |
| author_facet | Robert A Harrison George O Oluoch Stuart Ainsworth Jaffer Alsolaiss Fiona Bolton Ana-Silvia Arias José-María Gutiérrez Paul Rowley Stephen Kalya Hastings Ozwara Nicholas R Casewell |
| author_sort | Robert A Harrison |
| collection | DOAJ |
| description | <h4>Background</h4>Antivenom is the treatment of choice for snakebite, which annually kills an estimated 32,000 people in sub-Saharan Africa and leaves approximately 100,000 survivors with permanent physical disabilities that exert a considerable socioeconomic burden. Over the past two decades, the high costs of the most polyspecifically-effective antivenoms have sequentially reduced demand, commercial manufacturing incentives and production volumes that have combined to create a continent-wide vacuum of effective snakebite therapy. This was quickly filled with new, less expensive antivenoms, many of which are of untested efficacy. Some of these successfully marketed antivenoms for Africa are inappropriately manufactured with venoms from non-African snakes and are dangerously ineffective. The uncertain efficacy of available antivenoms exacerbates the complexity of designing intervention measures to reduce the burden of snakebite in sub-Saharan Africa. The objective of this study was to preclinically determine the ability of antivenoms available in Kenya to neutralise the lethal effects of venoms from the most medically important snakes in East Africa.<h4>Methods</h4>We collected venom samples from the most medically important snakes in East Africa and determined their toxicity in a mouse model. Using a 'gold standard' comparison protocol, we preclinically tested the comparative venom-neutralising efficacy of four antivenoms available in Kenya with two antivenoms of clinically-proven efficacy. To explain the variant efficacies of these antivenoms we tested the IgG-venom binding characteristics of each antivenom using in vitro IgG titre, avidity and venom-protein specificity assays. We also measured the IgG concentration of each antivenom.<h4>Findings</h4>None of the six antivenoms are preclinically effective, at the doses tested, against all of the most medically important snakes of the region. The very limited snake polyspecific efficacy of two locally available antivenoms is of concern. In vitro assays of the abilities of 'test' antivenom IgGs to bind venom proteins were not substantially different from that of the 'gold standard' antivenoms. The least effective antivenoms had the lowest IgG content/vial.<h4>Conclusions</h4>Manufacture-stated preclinical efficacy statements guide decision making by physicians and antivenom purchasers in sub-Saharan Africa. This is because of the lack of both clinical data on the efficacy of most of the many antivenoms used to treat patients and independent preclinical assessment. Our preclinical efficacy assessment of antivenoms available in Kenya identifies important limitations for two of the most commonly-used antivenoms, and that no antivenom is preclinically effective against all the regionally important snakes. The potential implication to snakebite treatment is of serious concern in Kenya and elsewhere in sub-Saharan Africa, and underscores the dilemma physicians face, the need for clinical data on antivenom efficacy and the medical and societal value of establishing independent preclinical antivenom-efficacy testing facilities throughout the continent. |
| first_indexed | 2024-12-24T01:02:09Z |
| format | Article |
| id | doaj.art-6290f15992bb4bf1a83af208945cf200 |
| institution | Directory Open Access Journal |
| issn | 1935-2727 1935-2735 |
| language | English |
| last_indexed | 2024-12-24T01:02:09Z |
| publishDate | 2017-10-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj.art-6290f15992bb4bf1a83af208945cf2002022-12-21T17:23:20ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352017-10-011110e000596910.1371/journal.pntd.0005969Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa.Robert A HarrisonGeorge O OluochStuart AinsworthJaffer AlsolaissFiona BoltonAna-Silvia AriasJosé-María GutiérrezPaul RowleyStephen KalyaHastings OzwaraNicholas R Casewell<h4>Background</h4>Antivenom is the treatment of choice for snakebite, which annually kills an estimated 32,000 people in sub-Saharan Africa and leaves approximately 100,000 survivors with permanent physical disabilities that exert a considerable socioeconomic burden. Over the past two decades, the high costs of the most polyspecifically-effective antivenoms have sequentially reduced demand, commercial manufacturing incentives and production volumes that have combined to create a continent-wide vacuum of effective snakebite therapy. This was quickly filled with new, less expensive antivenoms, many of which are of untested efficacy. Some of these successfully marketed antivenoms for Africa are inappropriately manufactured with venoms from non-African snakes and are dangerously ineffective. The uncertain efficacy of available antivenoms exacerbates the complexity of designing intervention measures to reduce the burden of snakebite in sub-Saharan Africa. The objective of this study was to preclinically determine the ability of antivenoms available in Kenya to neutralise the lethal effects of venoms from the most medically important snakes in East Africa.<h4>Methods</h4>We collected venom samples from the most medically important snakes in East Africa and determined their toxicity in a mouse model. Using a 'gold standard' comparison protocol, we preclinically tested the comparative venom-neutralising efficacy of four antivenoms available in Kenya with two antivenoms of clinically-proven efficacy. To explain the variant efficacies of these antivenoms we tested the IgG-venom binding characteristics of each antivenom using in vitro IgG titre, avidity and venom-protein specificity assays. We also measured the IgG concentration of each antivenom.<h4>Findings</h4>None of the six antivenoms are preclinically effective, at the doses tested, against all of the most medically important snakes of the region. The very limited snake polyspecific efficacy of two locally available antivenoms is of concern. In vitro assays of the abilities of 'test' antivenom IgGs to bind venom proteins were not substantially different from that of the 'gold standard' antivenoms. The least effective antivenoms had the lowest IgG content/vial.<h4>Conclusions</h4>Manufacture-stated preclinical efficacy statements guide decision making by physicians and antivenom purchasers in sub-Saharan Africa. This is because of the lack of both clinical data on the efficacy of most of the many antivenoms used to treat patients and independent preclinical assessment. Our preclinical efficacy assessment of antivenoms available in Kenya identifies important limitations for two of the most commonly-used antivenoms, and that no antivenom is preclinically effective against all the regionally important snakes. The potential implication to snakebite treatment is of serious concern in Kenya and elsewhere in sub-Saharan Africa, and underscores the dilemma physicians face, the need for clinical data on antivenom efficacy and the medical and societal value of establishing independent preclinical antivenom-efficacy testing facilities throughout the continent.https://doi.org/10.1371/journal.pntd.0005969 |
| spellingShingle | Robert A Harrison George O Oluoch Stuart Ainsworth Jaffer Alsolaiss Fiona Bolton Ana-Silvia Arias José-María Gutiérrez Paul Rowley Stephen Kalya Hastings Ozwara Nicholas R Casewell Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. PLoS Neglected Tropical Diseases |
| title | Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. |
| title_full | Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. |
| title_fullStr | Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. |
| title_full_unstemmed | Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. |
| title_short | Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. |
| title_sort | preclinical antivenom efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in east africa |
| url | https://doi.org/10.1371/journal.pntd.0005969 |
| work_keys_str_mv | AT robertaharrison preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT georgeooluoch preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT stuartainsworth preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT jafferalsolaiss preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT fionabolton preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT anasilviaarias preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT josemariagutierrez preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT paulrowley preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT stephenkalya preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT hastingsozwara preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica AT nicholasrcasewell preclinicalantivenomefficacytestingrevealspotentiallydisturbingdeficienciesofsnakebitetreatmentcapabilityineastafrica |